Education
About Us
Working with TipRanks
Follow Us
OnKure Therapeutics (OKUR)
NASDAQ:OKUR
Total Valuation
OnKure Therapeutics has a market cap or net worth of $27.43M. The enterprise value is -$37.98M.
Market Cap$27.43M
Enterprise Value-$37.98M
Share Statistics
OnKure Therapeutics has 12,823,872 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding12,823,872
Owned by Insiders8.71%
Owned by Institutions0.03%
Financial Efficiency
OnKure Therapeutics’s return on equity (ROE) is -0.51 and return on invested capital (ROIC) is -51.84%.
Return on Equity (ROE)-0.51
Return on Assets (ROA)-0.46
Return on Invested Capital (ROIC)-51.84%
Return on Capital Employed (ROCE)-0.52
Revenue Per Employee0.00
Profits Per Employee-1.15M
Employee Count46
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of OnKure Therapeutics is ―. OnKure Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value1.10
Price to FCF0.00
Price to Operating Cash Flow-0.56
PEG Ratio―
Income Statement
In the last 12 months, OnKure Therapeutics had revenue of 0.00 and earned -52.67M in profits. Earnings per share was -3.95.
Revenue0.00
Gross Profit0.00
Operating Income-54.39M
Pretax Income-52.67M
Net Income-52.67M
EBITDA-51.71M
Earnings Per Share (EPS)-3.95
Cash Flow
In the last 12 months, operating cash flow was 9.38M and capital expenditures -50.00K, giving a free cash flow of 9.33M billion.
Operating Cash Flow9.38M
Free Cash Flow9.33M
Free Cash Flow per Share0.73
Dividends & Yields
OnKure Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.51
52-Week Price Change-85.51%
50-Day Moving Average2.44
200-Day Moving Average6.23
Relative Strength Index (RSI)27.80
Average Volume (3m)67.46K
Important Dates
OnKure Therapeutics upcoming earnings date is Aug 12, 2025, Before Open (Confirmed).
Last Earnings DateMay 6, 2025
Next Earnings DateAug 12, 2025
Ex-Dividend Date―
Financial Position
OnKure Therapeutics as a current ratio of 10.73, with Debt / Equity ratio of 1.05%
Current Ratio10.73
Quick Ratio10.73
Debt to Market Cap0.00
Net Debt to EBITDA2.12
Interest Coverage Ratio-181.29
Taxes
In the past 12 months, OnKure Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
OnKure Therapeutics EV to EBITDA ratio is -0.10, with an EV/FCF ratio of -0.10.
EV to Sales0.00
EV to EBITDA-0.10
EV to Free Cash Flow-0.10
EV to Operating Cash Flow-0.10
Balance Sheet
OnKure Therapeutics has $96.66M in cash and marketable securities with $955.00K in debt, giving a net cash position of -$95.71M billion.
Cash & Marketable Securities$96.66M
Total Debt$955.00K
Net Cash-$95.71M
Net Cash Per Share-$7.46
Tangible Book Value Per Share$7.78
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for OnKure Therapeutics is $26.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$26.50
Price Target Upside1225.00% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast73.12%